Cybin Inc. is a Canada-based biotechnology company. The Company is focused on progressing Psychedelics to therapeutics by engineering drug discovery platforms, drug delivery systems, formulation approaches and treatment regimens for mental health disorders. Across the various research and development programs, the Company is researching and developing an array of synthetic psychedelic active pharmaceutical ingredients (API) intended to be delivered through drug delivery systems, including sublingual films1, orally disintegrating tablets (ODT)2, via inhalation and via intravenous (IV). Its drug programs include Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Anxiety Disorders (CYB004) and Neuroinflammation (CYB005). The Company focuses on the clinical development path for CYB004, the Company's deuterated Phase 1 N,N-dimethyltryptamine (DMT) molecule, for the treatment of anxiety disorders. Its subsidiaries include Cybin Corp., Natures Journey Inc, and others.
|
|
|
|
|
TD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts.
Date | Event description | Earnings per share actual | Earnings estimate range | Previous year's actual |
---|---|---|---|---|
November 14, 2022 | Q2 2023 Earnings Release | -$0.047 | -$0.064 to -$0.039 | -$0.088 |
August 8, 2022 | Q1 2023 Earnings Release | -$0.055 | -$0.079 to -$0.063 | -- |
June 22, 2022 | Q4 2022 Earnings Release | -$0.079 | -$0.08 to -$0.071 | -- |
February 10, 2022 | Q3 2022 Earnings Release | -$0.08 | -$0.088 to -$0.072 | -- |
Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.
, , , Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.